

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. A post-hoc analysis of the Phase III RxPONDER trial evaluating the addition of adjuvant chemotherapy to standard endocrine therapy for women with invasive breast cancer found that low levels of anti-müllerian hormone (AMH) in premenopausal women ...**

  - Were not associated with adjuvant chemotherapy benefit
  - Were associated with less benefit from adjuvant chemotherapy than medium or high AMH levels
  - Were associated with more benefit from adjuvant chemotherapy than medium or high AMH levels
- 2. Which of the following statements best describes outcomes with sacituzumab govitecan (SG) for patients with HR-positive, HER2-negative metastatic breast cancer in the Phase III TROPICS-02 trial?**

  - No improvement in progression-free survival (PFS) or overall survival (OS)
  - Improvement in PFS but not in OS
  - Improvement in PFS and OS
- 3. Which of the following metrics was significantly improved for patients with metastatic castration-resistant prostate cancer with a homologous recombination repair gene mutation that progressed on a prior next-generation hormonal agent who received olaparib monotherapy versus abiraterone or enzalutamide in the Phase III PROfound trial?**

  - Imaging-based PFS
  - OS
  - Both imaging-based PFS and OS
  - Neither imaging-based PFS nor OS
- 4. In the Phase III EMBARK trial, which of the following regimens demonstrated an improvement in metastasis-free survival compared to leuprolide alone for patients with high-risk biochemically recurrent prostate cancer?**

  - Enzalutamide and leuprolide
  - Enzalutamide alone
  - Both enzalutamide/leuprolide and enzalutamide alone
  - Neither enzalutamide/leuprolide nor enzalutamide alone
- 5. According to data from the Phase III TROPION-Lung01 trial, datopotamab deruxtecan appears to be more efficacious in patients with which type of previously treated advanced non-small cell lung cancer?**

  - Squamous
  - Nonsquamous
  - Neither of the above; patients with either histology benefited equally
- 6. Ifinotamab deruxtecan targets which of the following proteins?**

  - HER2
  - HER3
  - TROP2
  - B7-H3
- 7. Which of the following adverse events was most commonly reported among patients receiving loncastuximab tesirine for relapsed/refractory (R/R) diffuse large B-cell lymphoma in the Phase II LOTIS-2 trial?**

  - Blurred vision
  - Increased gamma-glutamyl transferase levels
  - Peripheral neuropathy
  - Hypoglycemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

8. What was the approximate overall response rate observed with pirtobrutinib for patients with R/R chronic lymphocytic leukemia and prior exposure to a Bruton tyrosine kinase inhibitor in the Phase I/II BRUIN study?
- a. 22%
  - b. 42%
  - c. 62%
  - d. 82%
9. Which of the following descriptions best reflects the results from the Phase I/II LINKER-MM1 trial of linvoseltamab for patients with R/R multiple myeloma (MM)?
- a. Low response rate (<30%) with short duration of response (DOR) (median DOR ~9 months)
  - b. Low response rate (<30%) with durable responses (median DOR ~29 months)
  - c. High response rate (>70%) with short duration of response (median DOR ~9 months)
  - d. High response rate (>70%) with durable responses (median DOR ~29 months)
10. Which of the following outcomes best describes the results of the Phase III PERSEUS trial with subcutaneous daratumumab in combination with bortezomib, lenalidomide and dexamethasone (VRd) versus VRd, both as induction therapy, followed by lenalidomide maintenance for patients with newly diagnosed transplant-eligible MM?
- a. No significant improvement in PFS or OS
  - b. Significant improvement in PFS with favorable trend toward improved OS
  - c. Significant improvement in PFS and OS